title: Adjuvant Treatment of High-risk Renal Cell Carcinoma: Leaving the Desert?
abstract: In a recent trial, adjuvant treatment with sunitinib significantly prolonged disease-free survival compared to placebo. This positive result is muted by the rate of side effects and overtreatment, raising the question of proper patient and agent selection in the adjuvant setting.
authors.affiliation: Department of Urology, Ernst-Moritz-Arndt-University, Greifswald, Germany. Electronic address: md.nkroeger@gmail.com.
authors.forename: Nils
authors.initials: N
authors.lastname: Kroeger
authors.affiliation: Department of Urology, Eberhard Karls University, Tübingen, Germany.
authors.forename: Arnulf
authors.initials: A
authors.lastname: Stenzl
authors.affiliation: Department of Urology, Ernst-Moritz-Arndt-University, Greifswald, Germany.
authors.forename: Martin
authors.initials: M
authors.lastname: Burchardt
authors.affiliation: Department of Urology, Eberhard Karls University, Tübingen, Germany. Electronic address: bedke@live.com.
authors.forename: Jens
authors.initials: J
authors.lastname: Bedke
mesh_terms: D002292:Carcinoma, Renal Cell / Q000188:drug therapy*; D017024:Chemotherapy, Adjuvant; D018572:Disease-Free Survival; D006801:Humans; D007211:Indoles / Q000627:therapeutic use; D007680:Kidney Neoplasms / Q000188:drug therapy*; D009392:Nephrectomy; D009536:Niacinamide / Q000031:analogs & derivatives / Q000627:therapeutic use; D010671:Phenylurea Compounds / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011758:Pyrroles / Q000627:therapeutic use; D012306:Risk; D018570:Risk Assessment; D000077157:Sorafenib; D000077210:Sunitinib; D015996:Survival Rate; D016896:Treatment Outcome
chemical_list: D007211:Indoles; D010671:Phenylurea Compounds; D047428:Protein Kinase Inhibitors; D011758:Pyrroles; D009536:Niacinamide; D000077157:Sorafenib; D000077210:Sunitinib